GoodRx Holdings, Inc. (GDRX)

NMS – Цена в реальном времени. Валюта: USD

2.80

+0.11 (4.09%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

2.80

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 7:16 PM EDT

27.05.2026

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion tu.

20.05.2026

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

GoodRx Holdings, Inc. faces ongoing revenue and margin pressure as its legacy business declines and Pharma Direct grows but with lower profitability. GDRX's Q1 results showed a 4% Y/Y revenue drop and EBITDA margin compression to 18.5%, with management expecting continued legacy erosion through 2026. Valuation sensitivity is highest to margin assumptions; the base DCF value is $2.49/share, near the current price, with scenario analysis skewed toward downside risk.

08.05.2026

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

07.05.2026

Big Pharma Runs Its Checkout Counter Through GoodRx

Out-of-pocket drug costs are rising for millions of Americans. Coverage gaps are widening.

07.05.2026

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.

07.05.2026

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

06.05.2026

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.09 per share a year ago.

Видео

No Data

There is no data to display

Пресс-релизы

27.05.2026

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

06.05.2026

GoodRx Reports First Quarter 2026 Results

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2026. First Quarter 2026 Highlights Revenue of $194.0 million Net income of $1.2 million; Net income margin of 0.6% Adjusted Net Income1 of $23.0 million; Adjusted Net Income Margin1 of 11.9% Adjusted EBITDA1 of $58.3 million; Adjusted EBITDA Margin1 of 30.

15.04.2026

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that the new higher dose Wegovy® HD (semaglutide) injection 7.2 mg is now available to eligible self-pay patients on GoodRx at $399 per month. Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost. For patients, Wegovy HD offers an.

09.04.2026

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo™ (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. The offering provides transparent pricing and nationwide.

GoodRx Holdings, Inc. (GDRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

GoodRx Holdings, Inc. (GDRX)

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Big Pharma Runs Its Checkout Counter Through GoodRx

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

Видео

No Data

Пресс-релизы

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx Reports First Quarter 2026 Results

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Big Pharma Runs Its Checkout Counter Through GoodRx

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

Видео

No Data

Пресс-релизы

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx Reports First Quarter 2026 Results

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

Search stocks

GoodRx Holdings, Inc. (GDRX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

GoodRx Holdings, Inc. (GDRX)

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Big Pharma Runs Its Checkout Counter Through GoodRx

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

Видео

No Data

Пресс-релизы

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx Reports First Quarter 2026 Results

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

Big Pharma Runs Its Checkout Counter Through GoodRx

Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

Видео

No Data

Пресс-релизы

GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

GoodRx Reports First Quarter 2026 Results

GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide